Assessment of Ovarian Toxicity in Premenopausal Adults During Drug Development for Oncologic Products
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
November 26, 2024
November 26, 2024
c3b8f633-4560-4ecf-a713-34ac782330d1
Related Documents
Drug Master Files Guidance for Industry
Guidance DocumentNovember 15, 2019Center for Drug Evaluation and Research
Tissue Agnostic Drug Development in Oncology: Draft Guidance for Industry
Guidance DocumentOctober 17, 2022Office of the Commissioner
Combined Food and Drug Administration and Sponsor Oncologic Drugs Advisory Committee Briefing Document
Guidance DocumentDecember 27, 2024Office of the Commissioner
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox